
    
      This is a multi-center, randomized study to demonstrate the efficacy and safety of 2 starting
      doses of ponatinib as a treatment for CP-CML compared to nilotinib. Eligible patients must
      have chronic phase chronic myeloid leukemia (CP-CML), be resistant to first-line imatinib
      treatment and have received no other tyrosine kinase inhibitors (TKIs).
    
  